Meta-Analysis Comparing the Relative Risk of Adverse Events for Amiodarone Versus Placebo

Amiodarone has been associated with adverse events that may restrict its use. We performed a meta-analysis of placebo-controlled trials to assess the relative risk of adverse events of amiodarone compared with placebo. In total, 43 randomized trials were included. A total of 11,395 patients were inc...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2019-12, Vol.124 (12), p.1889-1893
Main Authors: Ruzieh, Mohammed, Moroi, Morgan K., Aboujamous, Nader M., Ghahramani, Mehrdad, Naccarelli, Gerald V., Mandrola, John, Foy, Andrew J.
Format: Article
Language:English
Subjects:
Amiodarone
Amiodarone - adverse effects
Amiodarone - therapeutic use
Anti-Arrhythmia Agents - adverse effects
Anti-Arrhythmia Agents - therapeutic use
Arrhythmias, Cardiac - diagnosis
Arrhythmias, Cardiac - drug therapy
Clinical trials
Drug dosages
Drug-Related Side Effects and Adverse Reactions - epidemiology
Drug-Related Side Effects and Adverse Reactions - etiology
Drug-Related Side Effects and Adverse Reactions - physiopathology
Female
Humans
Incidence
Liver
Male
Meta-analysis
Pulmonary fibrosis
Randomization
Randomized Controlled Trials as Topic
Reference Values
Risk analysis
Risk Assessment
Severity of Illness Index
Statistical analysis
Studies
Thyroid
Thyroid gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Amiodarone has been associated with adverse events that may restrict its use. We performed a meta-analysis of placebo-controlled trials to assess the relative risk of adverse events of amiodarone compared with placebo. In total, 43 randomized trials were included. A total of 11,395 patients were included (5,792 patients randomized to amiodarone and 5,603 patients randomized to placebo). The incident rate of adverse events per 10,000 person-years was higher in the amiodarone group compared with placebo for pulmonary (129 vs 74; relative risk (RR) 1.77, p = 0.002), thyroid (201 vs 42; RR 4.44, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2019.09.008